Jacobs Levy Equity Management Inc. Trims Stock Position in CytomX Therapeutics, Inc. $CTMX

Jacobs Levy Equity Management Inc. cut its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 55.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 686,208 shares of the biotechnology company’s stock after selling 861,007 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.85% of CytomX Therapeutics worth $436,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Millennium Management LLC boosted its stake in shares of CytomX Therapeutics by 25.8% during the fourth quarter. Millennium Management LLC now owns 3,221,012 shares of the biotechnology company’s stock valued at $3,318,000 after purchasing an additional 660,756 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in CytomX Therapeutics by 18.6% during the first quarter. Assenagon Asset Management S.A. now owns 711,454 shares of the biotechnology company’s stock worth $452,000 after buying an additional 111,604 shares during the period. Northern Trust Corp boosted its position in CytomX Therapeutics by 16.0% during the 4th quarter. Northern Trust Corp now owns 150,632 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 20,746 shares in the last quarter. RA Capital Management L.P. bought a new stake in CytomX Therapeutics during the 1st quarter valued at $636,000. Finally, Tidal Investments LLC increased its holdings in shares of CytomX Therapeutics by 55.5% in the 4th quarter. Tidal Investments LLC now owns 382,529 shares of the biotechnology company’s stock valued at $394,000 after acquiring an additional 136,528 shares during the period. 67.77% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Oppenheimer started coverage on CytomX Therapeutics in a research note on Thursday, July 31st. They set an “outperform” rating and a $7.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, CytomX Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $5.75.

CytomX Therapeutics Stock Down 4.3%

Shares of CTMX opened at $2.00 on Friday. The company has a market cap of $329.82 million, a price-to-earnings ratio of 3.57 and a beta of 2.18. CytomX Therapeutics, Inc. has a twelve month low of $0.40 and a twelve month high of $3.10. The company has a 50 day moving average of $2.20 and a two-hundred day moving average of $1.66.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.